Prognostic significance of p53 gene alterations in node-negative breast cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Breast Cancer Research and Treatment

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF00665800PMID 8251647
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The p53 tumour suppressor gene

  1998cited by this paper
• Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

  1993cited by this paper
• Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.

  1992cited by this paper
• p53 mutations occur in aggressive breast cancer.

  1992cited by this paper
• Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

  1992cited by this paper
• p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases.

  1991cited by this paper
• Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas.

  1991cited by this paper
• Relation between p53 overexpression and established prognostic factors in breast cancer.

  1991cited by this paper
• Mutations in p53 as potential molecular markers for human breast cancer.

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines.

  1991cited by this paper
• Maintenance of p53 alterations throughout breast cancer progression.

  1991cited by this paper
• p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study

  1991cited by this paper
• Mutations in the p53 gene in primary human breast cancers.

  1991cited by this paper
• Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer.

  1991cited by this paper
• Accumulation of genetic alterations and progression of primary breast cancer.

  1991cited by this paper
• Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• Polymorphism at codon 213 within the p53 gene.

  1991cited by this paper
• A germ line mutation in exon 5 of the p53 gene in an extended cancer family.

  1991cited by this paper
• Instruction-Level Parallel Processing

  1991cited by this paper
• Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells.

  1990cited by this paper
• Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

  1990cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper
• Suppression of human colorectal carcinoma cell growth by wild-type p53.

  1990cited by this paper
• Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours.

  1990cited by this paper
• Wild-type p53 can inhibit oncogene-mediated focus formation.

  1989cited by this paper
• Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation

  1989cited by this paper
• A variation in the structure of the protein-coding region of the human p53 gene.

  1988cited by this paper
• Allele loss on short arm of chromosome 17 in breast cancers.

  1988cited by this paper
• P53 expression in breast cancer

  1988cited by this paper
• DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens

  1988cited by this paper
• The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13).

  1986cited by this paper
• Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation

  1984cited by this paper
• Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

  1984cited by this paper
• Histologic grading of breast cancer.

  1980cited by this paper
• Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

  1979cited by this paper
• Measurement of progesterone receptor in human breast cancer biopsies.

  1979cited by this paper
• Evaluation of estrogen receptor assays in human breast cancer tissue.

  1977cited by this paper
• Evaluation of estrogen receptor assays in human breast cancer tissue.

  1977cited by this paper

• ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers

  2022cites this paper
• Bone interface modulates drug resistance in breast cancer bone metastasis.

  2020cites this paper
• Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing

  2019cites this paper
• Biomarkers in Breast Cancer

  2018cites this paper
• Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.

  2017cites this paper
• Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

  2017cites this paper
• Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters.

  2016cites this paper
• Association of Histopathological Markers with Clinico- Pathological Factors in Mexican Women with Breast Cancer.

  2016cites this paper
• Pemetrexed, A Modulator of AMP-activated Kinase Signaling and an Inhibitor of Wild type and Mutant p53

  2015cites this paper
• The potential role of the oxidoreductase, NQO2, in breast cancer

  2015cites this paper
• Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy

  2015cites this paper
• Morphometric and Histological Study of Breast Lesions with Special Reference to Proliferative Activity and Invasiveness

  2013cites this paper
• MOLECULAR SUBTYPES IN BREAST CANCER

  2013cites this paper
• Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast Carcinoma

  2013cites this paper
• Mutant p53: one name, many proteins.

  2012cites this paper
• Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer

  2010cites this paper
• Serum autoantibodies as tumour markers in breast cancer: their role in screening, diagnosis and prognosis

  2009cites this paper
• Expression of p 27 KIP 1 , p 21 WAF 1 and p 53 does Not Correlate with Prognosis in Node-negative Invasive Ductal Carcinoma of the Breast

  2008cites this paper
• The prognostic value of p53 immunostaining in node-negative breast carcinoma.

  2007cites this paper
• Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer.

  2007cites this paper
• Conventional and new emerging prognostic factors in breast cancer: an update.

  2007cites this paper
• Association between the Estrogen Receptor α A908G Mutation and Outcomes in Invasive Breast Cancer

  2007cites this paper
• Das lokal fortgeschrittene Mammakarzinom: Bedeutung neuer und bekannter Prognosefaktoren für das Auftreten von Lokalrezidiven

  2007cites this paper
• The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer.

  2006cites this paper
• Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast.

  2006cites this paper
• Prognostic significance of immunohistochemical expression of p53 gene product in operable breast cancer.

  2006cites this paper
• Primary structure-based function characterization of BRCT domain replicates in BRCA1.

  2006cites this paper
• Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

  2006cites this paper
• Ki-67, p53, ER Receptors, Ploidy and S Phase as Long-Term Prognostic Factors in T1 Node-Negative Breast Cancer

  2006cites this paper
• Genetic Prognostic Index Influences Patient Outcome for Node-Positive Breast Cancer

  2006cites this paper
• Postoperative prognosis of node-negative breast cancers predicted by gene-expression profiling on a cDNA microarray of 25,344 genes

  2005cites this paper
• Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients

  2005cites this paper
• Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas

  2005cites this paper
• p53 in Human Cancer — Somatic and Inherited Mutations and Mutation-independent Mechanisms

  2005cites this paper
• The p53 Tumor Suppressor Pathway and Cancer

  2005cites this paper
• Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients.

  2004cites this paper
• in breast cancer

  2004cites this paper
• The p53 tumor suppressor gene in breast cancer

  2004cites this paper
• Expression profiling to predict postoperative prognosis for estrogen receptor‐negative breast cancers by analysis of 25,344 genes on a cDNA microarray

  2004cites this paper
• Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast.

  2004cites this paper
• Mutational spectrum of p53 mutations in primary breast and ovarian tumors.

  2004cites this paper
• Prognostic and predictive value of p53 and p21 in breast cancer

  2004cites this paper
• Combined modality management of breast cancer: development of predictive markers through proteomics.

  2003cites this paper
• Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma

  2003cites this paper
• Leader Biological indices in the assessment of breast cancer

  2003cites this paper
• Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.

  2002cites this paper
• p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.

  2002cites this paper
• STEPping into position: a new player in the NMDA receptor game.

  2002cites this paper
• Aplicación del índice pronóstico de Nottingham en el carcinoma de mama operable

  2002cites this paper
• Molecular targets in breast cancer: current status and future directions.

  2002cites this paper
• Prevalence and spectrum of p53 mutations associated with smoking in breast cancer.

  2002cites this paper
• P53 gene mutations: case study of a clinical marker for solid tumors.

  2002cites this paper
• Prognostic Factors in Node-Negative Breast Cancer: A Review of Studies With Sample Size More Than 200 and Follow-Up More Than 5 Years

  2002cites this paper
• The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.

  2001cites this paper
• Clinical Uses of Tumor Markers: A Critical Review

  2001cites this paper
• Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer.

  2001cites this paper
• Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma

  2001cites this paper
• [Local recurrence in premenopausal women with breast cancer: risk factors and effect of therapy].

  2001cites this paper
• Relevance of DNA-ploidy as a prognostic instrument for solid tumors.

  2000cites this paper
• Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas

  2000cites this paper
• Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.

  2000cites this paper
• Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.

  2000cites this paper
• Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism.

  2000cites this paper
• Alteration of a p53 Gene Status Affects Outcome of Patients with Recurrent Ovarian Cancer

  2000cites this paper
• P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up.

  2000cites this paper
• Hereditary breast cancer: a review.

  2000cites this paper
• Loss of heterozygosity at 3p24-p25 as a prognostic factor in breast cancer.

  2000cites this paper
• Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer.

  2000cites this paper
• p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.

  2000cites this paper
• P53 mutations analysis in benign and malignant breast lesions: Using needle rinses from fine‐needle aspirations

  2000cites this paper
• Clinical studies of p53 in treatment and benefit of breast cancer patients.

  1999cites this paper
• Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer

  1999cites this paper
• Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis

  1999cites this paper
• Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients.

  1998cites this paper
• Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary node negative breast cancer

  1998cites this paper
• p53--an acrobat in tumorigenesis.

  1998cites this paper
• Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.

  1998cites this paper
• Evaluation of an immunoluminometric based assay as a novel method for the quantitative analysis of p53 protein in tumor tissues.

  1998cites this paper
• Alterations of theTP53 gene and TP53 protein expression in epithelial ovarian cancer before and after chemotherapy

  1998cites this paper
• Immunohistochemical analysis of p53 expression in primary breast carcinomas.

  1998cites this paper
• Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma.

  1998cites this paper
• The molecular biology of breast cancer: accelerating clinical applications.

  1998cites this paper
• Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer.

  1998cites this paper
• The expression of the proliferating antigen Ki67, PCNA and products of suppressor gene p53 in primary invasive ductal breast carcinoma.

  1998cites this paper
• Biologic characteristics of breast cancer detected by mammography and by palpation in a screening program: a pilot study.

  1997cites this paper
• Prognostic and predictive factors in breast cancer.

  1997cites this paper
• Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy.

  1997cites this paper
• p53 mutations in breast cancer: incidence and relations to tumor aggressiveness and evolution of the disease.

  1997cites this paper
• Cytological evaluation of biological prognostic markers from primary breast carcinomas

  1997cites this paper
• Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer.

  1997cites this paper
• THE PATHOLOGICAL AND BIOLOGICAL NATURE OF SCREEN‐DETECTED BREAST CARCINOMAS: A MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY

  1997cites this paper
• Detection of p53 gene mutation by rapid PCR‐SSCP and its association with poor survival in breast cancer

  1997cites this paper
• The p53-positive phenotype of breast cancers.

  1997cites this paper
• P53 Accumulation in Primary Breast Cancer: A Comparison between Immunohistochemistry and a Novel Luminometric Immunoassay

  1997cites this paper
• Common patterns of genetic evolution in human solid tumors.

  1997cites this paper
• A novel quantitative immunoassay system for p53 using antibodies selected for optimum designation of p53 status.

  1997cites this paper
• Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy.

  1997cites this paper
• The molecular epidemiology of p53 gene mutations in human breast cancer.

  1997cites this paper
• The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.

  1996cites this paper
• Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.

  1996cites this paper